Intercept Pharmaceuticals' Above $300 -- More Mega Millions On The Way?

Jan 17 2014, 1:53pm CST | by

Anyone following the stock of Intercept Pharmaceuticals (NASDAQ:ICPT) closely cannot help but get dizzy. After racing from $72 to $497 last week, the stock corrected sharply this week–trading below $250 early in the week, before recovering nicely to above $300 in the last two days.

Does this mean that the correction is over? Are more mega millions on the way for the company’s shareholders?

We cannot say. What we can say is that this is a highly speculative stock for investors who have faith in the company’s prospects.

Intercept Pharmaceuticals develops innovative treatment for chronic diseases likeobeticholic acid, a bile acid analog (OCA), which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea.

That certainly sounds like a very promising compound, and last week it performed unexpectedly well in a clinical trial, sending the company’s stock soaring — as this development makes it very likely that the compound will receive FDA approval.

As one of commentators observed in a previous piece:

“People bid up stock for market potential. Stock trading is speculative in nature and nothing is pure black and white in the Bio-tech world. I think you need to understand some fundamentals of the statistics and clinical trials before you can comment on the likelihood of FDA approval. Currently, what investors perceived is based on 5% type I error rate. The actual error rate is much much smaller than 5%, given the fact that the phase II clinical trial was stopped much earlier than designed.”

Even so, before rushing to buy the stock at these levels, investors should understand three things:

First, we are still talking about a drug that is very likely to win FDA approval, not a drug that has already received approval.

Second, even if OCA passes the FDA test, it must subsequently pass the market test. Investors have to look no further than the fate of Dendreon’s drug PROVENGE and Affymax’s drug OMONTYS, neither of which performed well in market tests.

Third, even if OCA passes both the FDA and the market test, at the current market valuation, the company is valued close to 7 percent of the value of Amgen Inc., which has been around for more than three decades and has several blockbuster stocks in the market.

A valuation such as this makes Intercept Pharmaceuticals hardly a bargain, even if it successfully passes the FDA and the market test. That’s why I’ll still stay away from the stock.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Power outage across Bangladesh as national grid collapses
Dhaka, Nov 1 (IANS) Power outages Saturday hit several places in Bangladesh, including the capital Dhaka, due to the collapse of the national grid.
 
 
Drugs to abet cancer cells suicide found
London, Nov 1 (IANS) British scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells -- paving the way for new treatments.
 
 
Climate change threatens global health security: UNEP
San Juan, Nov 1 (IANS/EFE) The rapid propagation in recent years of infectious diseases such as Malaria, Chikungunya and even Ebola is one more example of how climate change threatens global health security.
 
 
US-Japan joint rain radar mission to end next year
Washington, Nov 1 (IANS) After 17 years of groundbreaking 3-D images of rain and storms, the joint NASA and Japan Aerospace Exploration Agency Tropical Rainfall Measuring Mission (TRMM) will come to an end next year, the US space agency said in a statement.
 
 
 

Latest from the Network

Power outage across Bangladesh as national grid collapses
Dhaka, Nov 1 (IANS) Power outages Saturday hit several places in Bangladesh, including the capital Dhaka, due to the collapse of the national grid. Reports of power cuts were coming in from several other places...
Read more on Business Balla
 
Space plane crash: Sir Branson 'shocked' but to 'persevere'
New York, Nov 1 (IANS) Richard Branson, founder of the Virgin Group, was "shocked and saddened" by the news of the Virgin Galactic passenger space plane crash but said that he would "persevere". The space plane...
Read more on Politics Balla
 
Drugs to abet cancer cells suicide found
London, Nov 1 (IANS) British scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells -- paving the way for new treatments. The combination of two drugs, called TRAIL...
Read more on Business Balla
 
Boko Haram leader says kidnapped girls married off
Lagos, Nov 1 (IANS) The leader of the Nigerian Boko Haram insurgents, Abubakar Shekau, has in a new video said the over 200 abducted schoolgirls have been married to members of the group. The video, released Friday,...
Read more on Politics Balla
 
Another Burkina Faso army officer claims power
Ouagadougou, Nov 1 (IANS) Burkina Faso's senior military officer Isaac Zida, who was in command of the presidential guard, Saturday announced via a televised speech that he has seized power as head of state during the...
Read more on Politics Balla
 
Climate change threatens global health security: UNEP
San Juan, Nov 1 (IANS/EFE) The rapid propagation in recent years of infectious diseases such as Malaria, Chikungunya and even Ebola is one more example of how climate change threatens global health security. "Climatic...
Read more on Politics Balla
 
Nine killed in Afghanistan suicide bombing
Kabul, Nov 1 (IANS) Nine security personnel were killed while 20 civilians were injured in a suicide car bombing in the eastern Afghan province of Lowgar Saturday, the provincial government spokesman said. "One...
Read more on Politics Balla
 
Al Pacino considered name change
Al Pacino considered changing his name to ''Sonny Scott'' when he started acting. The 74-year-old star was advised to alter his moniker when he began working in the movie industry because any stars with an ''ethnic...
Read more on Movie Balla